3 Reasons to Buy Oracle Stock Now Despite a 24% Drop in 6 Months

Oracle’s fiscal Q1 2027 OCI revenue rose 121% year over year to $7.4 billion, and its remaining performance obligations increased $209 billion to a record $664 billion. The company raised fiscal 2027 revenue guidance to at least $90 billion, but $28 billion in quarterly capex drove free cash flow to negative $5 billion; fiscal-year capex is expected at $90–$95 billion. Shares have fallen 24% over six months amid spending and competition concerns, while the article highlights Oracle’s AI and multicloud growth as potential supports.

Analysis

The debate is less about demand than whether Oracle can turn contracted AI demand into cash returns before capacity expansion and dilution erode per-share economics. High utilization supports pricing and near-term revenue conversion, but also leaves little operating slack: power, construction, GPU delivery or customer deployment delays could defer revenue while capex arrives first. RPO is not equivalent to near-term revenue; verify duration, cancellation terms, customer concentration and the share funded by prepayments or customer-owned hardware. Those structures would materially improve the cash-conversion thesis if confirmed.

Multicloud database distribution is a credible wedge: Oracle can monetize workloads running on competitors’ clouds without winning the full infrastructure stack. But it may also reinforce AWS, Azure and Google Cloud as customer-control points, while their custom chips and agent platforms pressure Oracle’s cost position. Application AI is a longer-dated retention/cross-sell option, not yet evidence of material incremental earnings; softer NetSuite growth argues against capitalizing announcements as near-term acceleration.

Near term, the Oct. 28 Investor Day is a catalyst for capex, funding and cash-flow detail, not automatically a positive event. Over 1–3 months, track cloud growth against capacity additions and guidance; over 6–18 months, the decisive test is whether backlog converts with stable margins and improving free cash flow. The article’s valuation comparison is insufficient on its own: verify the earnings basis and treatment of prior investment gains. The contrarian risk is that the market is discounting financing and execution, not overlooking growth.

Key Decisions for Investors

• Consider a small, staged ORCL long rather than buying the full position ahead of Investor Day. Add only if management provides credible capacity, funding and cash-conversion milestones; avoid treating the reported RPO as guaranteed revenue.
• Use the Oct. 28 event as a risk checkpoint: seek detail on backlog timing and terms, net cash capex, equity/debt funding, and the path from negative free cash flow to cash generation. If disclosure is vague or capex rises without stronger conversion evidence, do not add.
• Falsify the bullish thesis if OCI growth decelerates while capacity expands, utilization falls materially without corresponding revenue ramp, or capex and dilution keep increasing without improvement in free cash flow. Reassess after the next results and guidance update.
• Do not infer near-term earnings upside from agentic AI launches alone. Track measurable application bookings, retention or cross-sell contribution; absent evidence, value these as a longer-term option rather than a current earnings driver.